| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2005;36:1666.)
© 2005 American Heart Association, Inc.
Original Contributions |
From the Department of Medical Biosciences (S.N.-A., P.L., A.K.N., T.J., S.A.E., B.H., D.H.), Division of Medical and Clinical Genetics, and the Department of Public Health and Clinical Medicine (P-G.W., B.S., K.A.), Umeå University, Umeå, Sweden.
Correspondence to Dr Dan Holmberg, Department of Medical Biosciences, Division of Medical and Clinical Genetics, Umeå University, SE-901 87, Umeå, Sweden. E-mail dan.holmberg{at}medbio.umu.se
| Abstract |
|---|
|
|
|---|
Methods A total of 56 families with 117 affected individuals were included in the linkage study. Genotyping was performed with polymorphic microsatellite markers with an average distance of 4.5 cM on chromosome 5. In the association study, 275 cases of first-ever stroke were included together with 550 matched community controls. Polymorphisms were tested individually for association of PDE4D to stroke.
Results Maximum allele-sharing lod score in favor of linkage was observed at marker locus D5S424 (lod score=2.06; P=0.0010). Conditional logistic regression calculations revealed no significant association of ischemic stroke to the defined at-risk allele in PDE4D (odds ratio, 1.1; 95% confidence interval, 0.84 to 1.45). A protective effect may though be implied for 2 of the polymorphisms analyzed in PDE4D.
Conclusions Using a candidate region approach in a set of stroke families from northern Sweden, we have replicated linkage of stroke susceptibility to the PDE4D gene region on chromosome 5q. Association studies in an independent nested case-control sample from the same geographically located population suggested that different alleles confer susceptibility/protection to stroke in the Icelandic and the northern Swedish populations.
Key Words: genetics phosphodiesterase inhibitors stroke
| Introduction |
|---|
|
|
|---|
90% of all stroke cases, with the majority being ischemic.1 Genetic components in human stroke has been implicated in several studies, including both twin studies2,3 and family studies.4,5 Animal models also suggest that susceptibility to ischemic stroke is influenced by genetic factors.6 In several rare monogenic forms of cerebrovascular diseases, the genetic components have been identified.7,8 For common forms of stroke, recent studies of Icelandic patients have demonstrated linkage to 5q12 and association between phosphodiesterase4D (PDE4D) and ischemic stroke.9,10 A suggested role of PDE4D in stroke pathogenesis is that PDE4D expression can influence the second messenger c-AMP, an important signal transduction molecule with many cellular functions, including smooth muscle cell proliferation.1113 To test the validity of these findings in a different population, we studied a family-based sample consisting of 56 nuclear and extended families, including 117 patients with ischemic or hemorrhagic stroke and a nested case-control sample, including 275 patients with ischemic or hemorrhagic stroke and 550 matched community controls, from the 2 northernmost counties of Sweden. | Materials and Methods |
|---|
|
|
|---|
Genotyping
For genotyping, DNA was extracted from 10 mL of donated and EDTA-treated blood using a standard phenol extraction method. Forty-three polymorphic microsatellite markers from ABI Prism Linkage Mapping Set version 2.5 HD5 were used for genotyping in the linkage study. To obtain an average interval between the markers of 4.5 cM, 1 marker was excluded because of uncertain genetic position and 2 markers were added. DNA (30 ng) and reagents to a reaction volume of 7.5 µL/well were pipetted in 96-well plates and performed as multiplex polymerase chain reactions (PCRs) on GeneAmpPCRSystem 9700 (Applied Biosystems). Reagent concentrations and the temperature profile were used as recommended for the Linkage Mapping Set. PCR products were pooled and diluted according to size and fluorescent dye type. Internal size standard (LIZ) and HiDi formamide were added before products were separated and detected on an ABI PRISM 3100 Genetic Analyzer. Data were assembled by 3100 DataCollection software version 1.1. Analysis of results, allele calling, and checks of quality and editing of called genotypes were performed using GeneMapperGenotyping software version 3.0. The genotypes were checked and, if necessary, edited manually. Applied Biosystems supplied all these software. To verify the family relationship and to detect genotype errors, data were checked for Mendelian inheritance using the program Pedcheck.17 For association analysis, we selected 3 single nucleotide polymorphism (SNP) markers based on information available from the public databases, rs1971940 (SNP1), rs716908 (SNP2), and rs294492 (SNP3). Sequences for 2 SNPs, rs12188950 (SNP 4, deCODE SNP 45), rs12153798, (SNP5, deCODE SNP 41) and 1 microsatellite (AC008818-1) were obtained by personal communication from Dr Solveig Gretarsdottir, deCODE, Iceland. We generated SNP genotypes using the TaqMan allelic discrimination method. TaqMan assays and reagents were from Applied Biosystems. PCRs were performed on GeneAmpPCRSystem 9700 PCR program according to the manufacturers instructions. ABI PRISM 7900HT Sequence Detection System was used to analyze TaqMan PCR products.
Statistical Analysis
We applied multipoint, nonparametric linkage analysis on chromosome 5 for confirmation of linkage to the region of STRK1 using the program Allegro.18 We used the spairs scoring function that assesses identity by descent (IBD) sharing among all pairs of affected individuals within families. This scoring function is suggested to perform well in all types of disease models19 and is also the scoring function used in the Icelandic stroke study.9 The nonparametric link (NPL) Z scores were converted into allele-sharing lod scores using the exponential model described elsewhere.20 When combining the family scores to obtain an overall score, we used a compromise between weighting the families equally and weighting the affected pairs equally, using the "power:0.5" option in Allegro. Allele frequencies were estimated among all individuals according to the algorithm of Merlin.21 We used the marker map of Genethon;22 for comparison, we also performed the analysis based on the deCODE genetic framework map.23 In the latter, interpolations with respect to the physical distances in NCBI genome build 34.3 and the available genetic positions in the deCODE map were made to come up with estimations of markers not included in this map. The probability values reported are computed by comparing the observed allele-sharing lod score with its complete data distribution and are not corrected for multiple testing. To estimate the significance of our findings and to adjust for the number of markers tested in a proper way, we did a simulation study over the candidate region. The simulations were made in Allegro using the same marker frequencies and pedigree structure as in the original analysis but with the assumption of no linkage. To test for association of genotypes and ischemic stroke in the case-control analysis, we calculated genotype-based odds ratios (ORs) with respective 95% confidence intervals (CIs) using conditional logistic regression. Indicator variables for the genotypes were constructed using individuals homozygous for the most common allele as the reference. Calculations were also performed under the assumption of an additive model, assigning the values of 0, 1, and 2 (according to each individuals number of variant alleles) to a genotype trend variable. All probability values presented are 2-tailed and not corrected for multiple testing. The association analysis in the case-control material was performed using the software package SPSS, version 11.5 (SPSS). For testing association in the family data set, we used the transmission/disequilibrium test within the program TRANSMIT, version 2.5.4, which has the advantage of allowing unknown parental genotypes.24 To avoid for bias using multiple affected individuals within a family in the presence of linkage, we used the robust estimate of the variance of the score vector. Linkage disequilibrium between markers was calculated by D' and R2 statistics in the case-control material using the program ldmax from the GOLD software package.25
| Results |
|---|
|
|
|---|
69 cM with an allele-sharing lod score of 200.9 When interpolating distances to markers without specified deCODE distances and adding these to the deCODE map, the allele-sharing lod scores changed marginally from the Genethon map, indicating that the differences could be caused by the decreased marker density in the analysis using the deCODE map. Excluding hemorrhagic strokes (n=15), had only a minor effect on the results (Figure 1). Further subphenotyping in the ischemic group was not considered because of the relatively small number of patients with validated carotid or cardiogenic stroke. The simulation study of 1000 random sets yielded a candidate region probability value of 0.01 for the allele-sharing lod score peak of 2.06 at marker D5S424. The candidate region was here assumed to be between the markers D5S1969 and D5S433, spanning over 51.1 cM and 12 markers. Together, these findings replicate previously reported evidence for the location of a locus conferring susceptibility to common forms of stroke at this chromosomal region.9
|
|
We next investigated if the reported association of ischemic stroke to the PDE4D gene10 could also be replicated in a nested case cohort from northern Sweden. For this we excluded all hemorrhagic cases, together with their controls. We performed a directed association study and included the microsatellite marker and the 2 SNPs reported by Gretarsdottir et al10 to display alleles with the strongest association to stroke. We also included 3 additional SNPs in the PDE4D gene that was genotyped before the Icelandic report of association of ischemic stroke to the PDE4D gene. The positions of the SNPs and the microsatellite marker in the PDE4D gene are shown in Figure 2. The markers used were found to be in Hardy-Weinberg equilibrium using
2 goodness-of-fit tests in the control group. Genotype frequencies and ORs of all the PDE4D markers analyzed are shown in Table 2. For 2 of the markers analyzed, conditional logistic regression calculations revealed association with P<0.05. SNP3 displayed an OR of 0.68 (95% CI, 0.48 to 0.96) and the "B" allele (4 bp compared with the shortest allele of CEPH 1347- 02) in AC008818-1 displayed an OR of 0.69 (95% CI, 0.49 to 0.98), assuming an additive model in both cases. Although when correcting for the number of markers and alleles tested probability values did not reach formal significance levels, this observation remains interesting. No significant association to the Icelandic defined at-risk allele 0 of AC008818-1, here denoted as allele C, was obtained in this study (OR, 1.1; 95% CI, 0.84 to 1.45) (Table 2). SNP4 and SNP5 were found to be in strong linkage disequilibrium (LD) with D' and R2 being close to 1. In addition, the microsatellite marker AC008818-1 (allele C) showed LD to SNP4 and SNP5, with D' values equal to 1, but with low R2 values (Table 3). These linkage disequilibrium data are consistent with those of the Icelandic study. Linkage disequilibrium data for all genotyped markers in the PDE4D gene are shown in Table 3. LD coverage is not complete because the association study primarily aimed to test the previously reported most significant disease-associated genetic markers: SNP 4, SNP 5, and AC008818-1. These markers were also analyzed for association to stroke in the family-based material, but no significant values for association were obtained (Table 4). Our data are unlikely to be confounded by population stratification because cases and controls were matched not only by sex, age, cohort, and date of health survey but also for place of domicile. All samples originate from the same geographical region in northern Sweden. The discrepancies between our data and those reported previously by Gretarsdottir et al10 may be because of population differences with alternative genotypes in this region contributing to stroke susceptibility in the northern Sweden population.
|
|
|
| Discussion |
|---|
|
|
|---|
|
Received November 29, 2004; revision received January 24, 2005; accepted February 14, 2005.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Bevan, M. Dichgans, A. Gschwendtner, G. Kuhlenbaumer, E.B. Ringelstein, and H. S. Markus Variation in the PDE4D Gene and Ischemic Stroke Risk: A Systematic Review and Meta-analysis on 5200 Cases and 6600 Controls Stroke, July 1, 2008; 39(7): 1966 - 1971. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Sherva, M. B. Miller, J. S. Pankow, S. C. Hunt, E. Boerwinkle, T. H. Mosley, A. B. Weder, J. D. Curb, A. Luke, A. C. Morrison, et al. A Whole-Genome Scan for Stroke or Myocardial Infarction in Family Blood Pressure Program Families Stroke, April 1, 2008; 39(4): 1115 - 1120. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. Wiklund, W. M. Brown, T. G. Brott, B. Stegmayr, R. D. Brown Jr, S. Nilsson-Ardnor, J. A. Hardy, B. M. Kissela, A. Singleton, D. Holmberg, et al. Lack of aggregation of ischemic stroke subtypes within affected sibling pairs Neurology, February 6, 2007; 68(6): 427 - 431. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nilsson-Ardnor, T. Janunger, P.-G. Wiklund, K. Lackovic, A. K. Nilsson, P. Lindgren, S. A. Escher, B. Stegmayr, K. Asplund, and D. Holmberg Genome-Wide Linkage Scan of Common Stroke in Families From Northern Sweden Stroke, January 1, 2007; 38(1): 34 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
J M Staton, M S Sayer, G J Hankey, J Attia, A Thakkinstian, Q Yi, V J Cole, R Baker, and J W Eikelboom Association between phosphodiesterase 4D gene and ischaemic stroke. J. Neurol. Neurosurg. Psychiatry, September 1, 2006; 77(9): 1067 - 1069. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Song, J. W. Cole, J. R. O'Connell, O. C. Stine, M. Gallagher, W. H. Giles, B. D. Mitchell, M. A. Wozniak, B. J. Stern, J. D. Sorkin, et al. Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study Hum. Mol. Genet., August 15, 2006; 15(16): 2468 - 2478. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. B. Worrall and J. C. Mychaleckyj PDE4D and Stroke: A Real Advance or a Case of the Emperor's New Clothes? Stroke, August 1, 2006; 37(8): 1955 - 1957. [Full Text] [PDF] |
||||
![]() |
V. H. Brophy, S. K. Ro, B. K. Rhees, L.-Y. Lui, J. M. Lee, N. Umblas, L. G. Bentley, J. Li, S. Cheng, W. S. Browner, et al. Association of Phosphodiesterase 4D Polymorphisms With Ischemic Stroke in a US Population Stratified by Hypertension Status Stroke, June 1, 2006; 37(6): 1385 - 1390. [Abstract] [Full Text] [PDF] |
||||
![]() |
G Kuhlenbaumer, K Berger, A Huge, E Lange, C Kessler, U John, H Funke, D G Nabavi, F Stogbauer, E B Ringelstein, et al. Evaluation of single nucleotide polymorphisms in the phosphodiesterase 4D gene (PDE4D) and their association with ischaemic stroke in a large German cohort J. Neurol. Neurosurg. Psychiatry, April 1, 2006; 77(4): 521 - 524. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Woo, R. Kaushal, B. Kissela, P. Sekar, M. Wolujewicz, P. Pal, K. Alwell, M. Haverbusch, I. Ewing, R. Miller, et al. Association of Phosphodiesterase 4D With Ischemic Stroke: A Population-Based Case-Control Study Stroke, February 1, 2006; 37(2): 371 - 376. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Markus and M. J. Alberts Update on Genetics of Stroke and Cerebrovascular Disease 2005 Stroke, February 1, 2006; 37(2): 288 - 290. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |